The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...

Biomedical engineer Nenad Bursac, standing, and postdoctoral associate Tianyu Wu image a heart tissue patch through a microscope at the Bursac lab at the Duke University Pratt School of Engineering.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...

Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...

The Product Shortage PLUS Endorsement was developed in consultation with Cell One Partners Inc., a world leader in helping cell and gene therapy companies advance and achieve growth objectives toward ...